Cargando…
Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer
Our previous studies demonstrated that specific inhibition of the BIG3-PHB2 complex, which is a critical modulator in estrogen (E2) signaling, using ERAP, a dominant negative peptide inhibitor, leads to suppression of E2-dependent estrogen receptor (ER) alpha activation through the reactivation of t...
Autores principales: | Yoshimaru, Tetsuro, Komatsu, Masato, Miyoshi, Yasuo, Honda, Junko, Sasa, Mitsunori, Katagiri, Toyomasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452155/ https://www.ncbi.nlm.nih.gov/pubmed/25736224 http://dx.doi.org/10.1111/cas.12654 |
Ejemplares similares
-
Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions
por: Yoshimaru, Tetsuro, et al.
Publicado: (2014) -
BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells
por: Kim, Nam-Hee, et al.
Publicado: (2015) -
Stapled BIG3 helical peptide ERAP potentiates anti-tumour activity for breast cancer therapeutics
por: Yoshimaru, Tetsuro, et al.
Publicado: (2017) -
Targeting BIG3–PHB2 interaction to overcome tamoxifen resistance in breast cancer cells
por: Yoshimaru, Tetsuro, et al.
Publicado: (2013) -
A-kinase anchoring protein BIG3 coordinates oestrogen signalling in breast cancer cells
por: Yoshimaru, Tetsuro, et al.
Publicado: (2017)